CLINICAL EXPERIENCE WITH PIRFENIDONE IN FIVE PATIENTS WITH SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE

被引：8

作者：

Miura, Yukiko ^{[1
,2
]}

Saito, Takefumi ^{[1
]}

Fujita, Kazutaka ^{[1
]}

Tsunoda, Yoshiya ^{[1
]}

Tanaka, Toru ^{[1
]}

Takoi, Hiroyuki ^{[1
]}

Yatagai, Yohei ^{[1
]}

Rin, Shigen ^{[1
]}

Sekine, Akimasa ^{[1
]}

Hayashihara, Kenji ^{[1
]}

Nei, Takahito ^{[2
]}

Azuma, Arata ^{[2
]}

机构：

[1] Natl Hosp Org, Ibarakihigashi Hosp, Dept Resp Med, Tokyo, Japan

[2] Nippon Med Sch, Dept Pulm Med & Oncol, Grad Sch Med, Tokyo, Japan

来源：

SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES | 2014年 / 31卷 / 03期

关键词：

Antifibrotic agent; interstitial lung disease; pirfenidone; scleroderma; vital capacity;

D O I：

暂无

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Interstitial lung disease is the most common complication and cause of death among patients with scleroderma. Scleroderma-related interstitial lung disease has usually been treated with cyclophosphamide; however, its effect was evaluated to be modest and long-term administration of this drug is associated with adverse effects. Herein, we report our clinical experience of administering pirfenidone, which is an antifibrotic agent, in five patients with scleroderma-related interstitial lung disease. All patients demonstrated an increase in vital capacity.

引用

页码：235 / 238

页数：4

共 50 条

[1] Scleroderma-related interstitial lung disease: principles of management
Das, Aparna
Kumar, Anupam
Arrossi, Andrea Valeria
Ghosh, Subha
Highland, Kristin B.
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (04) : 357 - 367
[2] Determining progression of scleroderma-related interstitial lung disease
Volkmann, Elizabeth R.
Tashkin, Donald P.
Sim, Myung
Kim, Grace Hyun
Goldin, Jonathan
Clements, Philip J.
JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2019, 4 (01) : 62 - 70
[3] Lung transplantation for scleroderma-related lung disease
Richardson, Claire B.
Singer, Jonathan P.
CURRENT PULMONOLOGY REPORTS, 2014, 3 (03) : 79 - 87
[4] Effect of mycophenolate sodium in scleroderma-related interstitial lung disease
Carmen Pilar Simeón-Aznar
Vicent Fonollosa-Plá
Carles Tolosa-Vilella
Albert Selva-O’Callaghan
Roser Solans-Laqué
Miquel Vilardell-Tarrés
Clinical Rheumatology, 2011, 30 : 1393 - 1398
[5] Lung transplantation for scleroderma-related lung disease
Claire B. Richardson
Jonathan P. Singer
Current Respiratory Care Reports, 2014, 3 (3): : 79 - 87
[6] Effect of mycophenolate sodium in scleroderma-related interstitial lung disease
Pilar Simeon-Aznar, Carmen
Fonollosa-Pla, Vicent
Tolosa-Vilella, Carles
Selva-O'Callaghan, Albert
Solans-Laque, Roser
Vilardell-Tarres, Miquel
CLINICAL RHEUMATOLOGY, 2011, 30 (11) : 1393 - 1398
[7] Quality of life in scleroderma-related interstitial lung disease and its association with respiratory clinical parameters
Ponniah, Thayalan
Wong, Chee Kuan
Ng, Choung Min
Raja, Jasmin
JOURNAL OF SCLERODERMA AND RELATED DISORDERS, 2025,
[8] Scleroderma-Related Lung Disease: Are Adipokines Involved Pathogenically?
Haley, Shannon
Shah, Dilip
Romero, Freddy
Summer, Ross
CURRENT RHEUMATOLOGY REPORTS, 2013, 15 (12)
[9] Scleroderma-Related Lung Disease: Are Adipokines Involved Pathogenically?
Shannon Haley
Dilip Shah
Freddy Romero
Ross Summer
Current Rheumatology Reports, 2013, 15
[10] Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease Results of Scleroderma Lung Study II
Tashkin, Donald P.
Volkmann, Elizabeth R.
Tseng, Chi-Hong
Roth, Michael D.
Khanna, Dinesh
Furst, Daniel E.
Clements, Philip J.
Theodore, Arthur
Kafaja, Suzanne
Kim, Grace Hyun
Goldin, Jonathan
Ariolla, Edgar
Elashoff, Robert M.
CHEST, 2017, 151 (04) : 813 - 820

← 1 2 3 4 5 →